Doseology Files Annual Information Form (AIF), Strengthening Public Disclosure Record AIF Filing Enhances Transparency and Provides Consolidated Disclosure for Investors

Rhea-AI Summary

Doseology (DOSED) filed its Annual Information Form (AIF) for the fiscal year ended June 30, 2025 on SEDAR+ to consolidate disclosure on business, strategy, risk factors, governance, and capital structure. The AIF aims to improve investor transparency and accessibility by combining information previously spread across multiple documents. The filing does not announce any financing or offering and is process-driven to maintain disclosure readiness and potential short-form prospectus eligibility under NI 44-101.

Key Figures

Fiscal year end: June 30, 2025 National Instrument: 44-101

2 metrics

Fiscal year end June 30, 2025 Fiscal year covered by the newly filed AIF

National Instrument 44-101 Short Form Prospectus Distributions eligibility framework referenced for AIF

Market Reality Check

Vol: Volume 0 shares vs 20-day...

normal vol

Volume Volume 0 shares vs 20-day average of 1800 shares ahead of this AIF filing. normal

Technical Price at 0 trades below the 200-day MA of 0.15, indicating pre-news weakness.

Market Pulse Summary

This announcement focused on Doseology’s filing of an AIF for the fiscal year ended June 30, 2025, c...

Analysis

This announcement focused on Doseology’s filing of an AIF for the fiscal year ended June 30, 2025, consolidating information on its business, risks, governance, and capital structure. Management emphasized that no financing or public offering was being launched and framed the filing as part of ongoing governance discipline and regulatory compliance, including potential short form prospectus eligibility under National Instrument 44-101. Investors may track future strategic or financing announcements against this enhanced disclosure baseline.

Key Terms

annual information form, aif, short form prospectus, national instrument 44-101, +3 more

7 terms

annual information form regulatory

"announced that it has filed its Annual Information Form ("AIF"), a key Canadian"

A company's annual information form is a comprehensive regulatory filing that lays out its business description, key assets, risks, legal matters and other background details shareholders need to understand the company’s operations. Think of it as a detailed owner’s manual or dossier that supplements financial statements, helping investors do deeper homework on how the business works and what could affect its future performance.

aif regulatory

"filed its Annual Information Form ("AIF"), a key Canadian public-company disclosure"

An alternative investment fund (AIF) is a pooled vehicle that gathers money from multiple investors to buy assets outside ordinary stocks and bonds—examples include private companies, real estate, hedge strategies, or commodities. It matters because AIFs offer different risk and return mixes, fees, and trading rules than public markets; think of them as a group buying a rental property together, where potential for higher returns comes with less frequent access to your cash and different costs.

short form prospectus regulatory

"does not constitute an application for, or assurance of, short-form prospectus eligibility"

A short form prospectus is a condensed legal document that gives investors the key facts about a company’s new securities offering—such as the offering size, price range, main financial highlights, and principal risks—without repeating full historical disclosures. It matters because it speeds up and simplifies the process of buying newly issued stock or bonds while still giving investors a focused “fact sheet” to compare the deal’s terms and risks, much like a product brochure that complements an existing full manual.

national instrument 44-101 regulatory

"short form prospectus eligible pursuant to National Instrument 44-101 – Short Form"

A Canadian securities regulation that sets the rules for using a short-form prospectus when a company offers securities to the public across provinces, specifying what information must be disclosed and how the offering is conducted. It matters to investors because it creates a standardized, checklist-style presentation of key facts about the issuer and the deal—like a clear, required information sheet—so buyers can compare offerings and know there are regulatory safeguards and timelines in place.

short form prospectus distributions regulatory

"pursuant to National Instrument 44-101 – Short Form Prospectus Distributions."

A short form prospectus distribution is a fast-track offering of new shares or other securities by a company that has already been regularly reporting its financials to regulators, allowing the company to sell securities without repeating full disclosure paperwork. For investors it matters because these offerings provide a quick way for companies to raise capital—similar to a shortcut lane at a store checkout—affecting share supply, potential dilution, and trading liquidity while still relying on previously published financial information.

sedar+ regulatory

"fiscal year ended June 30, 2025 on SEDAR+."

SEDAR+ is Canada’s centralized online system where publicly traded companies submit required regulatory documents such as financial reports, prospectuses and disclosure statements. It gives investors a single, searchable place — like a public library or online filing cabinet — to check a company’s official records for transparency, compare performance, and verify material information before making investment decisions.

capital markets financial

"No financing transaction, public offering, or capital markets activity is being announced"

Capital markets are places where people and organizations buy and sell long-term investments like stocks and bonds. They help connect those who need money to grow or fund projects with investors looking to earn returns over time. For investors, capital markets are important because they offer opportunities to invest, save, and grow their wealth through a variety of financial assets.

AI-generated analysis. Not financial advice.

KELOWNA, BC, Jan. 16, 2026 /PRNewswire/ -- Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) ("Doseology" or the "Company") a leader in biotechnology-driven consumer products, today announced that it has filed its Annual Information Form ("AIF"), a key Canadian public-company disclosure document, for the fiscal year ended June 30, 2025 on SEDAR+.

The filing of the AIF reflects Doseology's continued focus on maintaining strong public-company disclosure practices and provides investors with a consolidated reference covering the Company's business, strategy, risk factors, governance practices, and capital structure.

Enhanced Transparency for Investors

The AIF consolidates information that is otherwise distributed across multiple disclosure documents into a single, structured filing intended to improve accessibility and usability for shareholders and the broader investment community. Management believes that clear, well-organized disclosure supports informed analysis and long-term investor understanding of the Company.

"High-quality disclosure is not just a regulatory requirement — it is a critical part of how we build trust with shareholders over time," said Chris Jackson, Chief Executive Officer of Doseology.

"Filing our AIF reflects our commitment to clarity, consistency, and discipline in how we communicate as a public company, while continuing to focus on thoughtful execution of our strategy."

Governance Discipline and Capital Markets Context

Maintaining an up-to-date AIF is a standard component of public-company governance and forms part of Doseology's broader approach to responsible stewardship and regulatory compliance. While the Company regularly evaluates strategic, operational, and financing alternatives in the ordinary course of business, the filing of an AIF does not constitute an application for, or assurance of, short-form prospectus eligibility, nor does it represent a decision to pursue any public offering or financing at this time.

By maintaining a current disclosure record, the Company seeks to preserve flexibility under Canadian securities laws should future circumstances warrant, subject to regulatory requirements, market conditions, and internal approvals.

No Financing Announced

No financing transaction, public offering, or capital markets activity is being announced as a result of this filing. Any future financing, if undertaken, would be evaluated carefully in light of prevailing market conditions, regulatory considerations, and the Company's long-term strategic priorities. Notwithstanding, one of the motivations for the filing of the AIF is to enable to Corporation to be short form prospectus eligible pursuant to National Instrument 44-101 – Short Form Prospectus Distributions.

Why Now

Doseology filed its AIF to consolidate disclosure as the Company's operating profile has evolved, including platform development and its first acquisition. Management viewed this as the appropriate point to provide investors with a clearer, single reference reflecting the Company's current scope, risks, and governance practices. The filing is process-driven and not connected to any financing or capital markets transaction.

Availability of Disclosure

The Company's AIF and other continuous disclosure documents are available under Doseology's profile on SEDAR+ at www.sedarplus.ca.

About Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70)

Doseology Sciences Inc. operates in the oral stimulant sector as a next-generation platform intended to reshape how consumers access energy, stimulation, and nutraceutical products through better-for-you formats. The Company emphasizes product innovation, intellectual property development, capacity ownership, and disciplined commercial execution, and pursues measured growth and scalability through internal development and selective strategic acquisitions.

For more information:

https://doseology.com
https://feedthatbrain.com

On behalf of the Board of Directors, Chris Jackson
CEO, Director
Doseology Sciences Inc.

For more information, please contact the Company at:
Email: hello@doseology.com
Phone: 604.908.3095

---

Forward Looking Statements

This press release contains statements that constitute "forward‐looking information" within the meaning of applicable securities laws. Forward‐looking information is often identified by the words "may," "would," "could," "should," "will," "intend," "plan," "anticipate," "believe," "estimate," "expect" or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company's management's expectations, estimates or projections concerning the business of the Company's future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; and compliance with government regulation and related costs.. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. For more information, investors should review the Company's filings which are available on SEDAR+.

No securities regulatory authority has either approved or disapproved of the contents of this press release.

Logo: https://mma.prnewswire.com/media/2858641/5721412/Doseology_Sciences_Inc_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/doseology-files-annual-information-form-aif-strengthening-public-disclosure-record-aif-filing-enhances-transparency-and-provides-consolidated-disclosure-for-investors-302663532.html

SOURCE Doseology Sciences Inc.

FAQ

What did Doseology (DOSED) file on January 16, 2026?

Doseology filed its Annual Information Form (AIF) for the fiscal year ended June 30, 2025 on SEDAR+.

Does the AIF filing by Doseology (DOSED) announce a financing or public offering?

No. The AIF filing does not announce any financing, public offering, or capital markets transaction.

Why did Doseology (DOSED) file an AIF now and what does it enable?

Doseology filed the AIF to consolidate disclosure after business changes, including its first acquisition, and to maintain readiness for potential short-form prospectus eligibility under NI 44-101.

Where can investors access Doseology's (DOSED) AIF and disclosure documents?

Investors can view the AIF and other continuous disclosure under Doseology's profile on SEDAR+ at www.sedarplus.ca.

Does filing the AIF commit Doseology (DOSED) to pursue future financing?

No. The filing preserves flexibility but does not constitute a decision or assurance to pursue any financing; future actions would depend on approvals and market conditions.